Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Long Term Impact of Transplant & Survivorship for Sickle Cell Patients

    Contains 1 Component(s) Includes a Live Web Event on 09/29/2021 at 1:00 PM (EDT)

    Join us on September 29 at 12 PM CT, for the fourth and final webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on guidelines for post-transplant care and updated CIBMTR outcomes data.

    Join us on September 29 at 12 PM CT, for the fourth and final webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on guidelines for post-transplant care and updated CIBMTR outcomes data. Other topics include:

    - Expectations for organ function and recovery
    - Ongoing psychosocial supports for patients and their families
    - Updated outcomes data from CIBMTR, including: overall survival and subsequent cancers after transplant

    This webinar will be moderated by Dr. Rachel Phelan, and feature presentations by Dr. Mary Eapen from the Medical College of Wisconsin, and Dr. Elizabeth Stenger from UPMC Children's Hospital of Pittsburgh. Each webinar in this series will also highlight patient's lived experiences within each of the topics.

    There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar by emailing info@astct.org. This webinar will be recorded and the recording and slides will be posted 24-48 hours after the live event.

    Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    Continuing Medical Education Information

    This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.                

    Statement of Need:

    The Sickle Cell Warriors Program at NMDP is a patient services program that assists in typing for patients, financial assistance, counseling, patient education and providing peer connections. The primary feedback from patients in the Sickle Cell Warrior Program is that #1 barrier to treatment is physicians. Patients report that they are not being told about all of their treatment options; regardless of disease severity, they should at least be made aware of various options, but often they are not. Many patients go to the Sickle Cell Warriors Program to enroll in a clinical trial for transplant, but this usually does not cover cost of HLA typing. In this case, the referring physician has not gone through the process of HLA typing, either because of misinformation or because the physician refuses to provide an order for typing simply because they don’t agree with patients physicians. This is a clear miscommunication between the community oncologists and transplant physicians. In surveys, transplant physicians identify a lack of awareness, lack of confidence, and reliance on outdated data from the referring physicians. These referring physicians in a similar survey reported that their primary reason for not communicating all treatment options was noncompliance in patients who they did not believe had the means to move forward with treatment. This illustrates a complex problem between the three groups (referring community physicians, transplant physicians, and the patients themselves) that this webinar series aims to address.

    Target Audience:

    This activity is intended for physicians, both referring physicians and transplant specialists, scientists, and other healthcare professionals who are part of the multidisciplinary team.

    Learning Objectives:

    Upon completion of this education activity, participants will be able to:

    1. Describe the long term psychosocial impacts in patients and their caregivers after transplant, and identify potential supports for long term survivorships.

    2. Define the general guidelines for post-transplant care in order to set expectations for patients in their recovery.

    3. Summarize trends in outcomes data, including rates of subsequent cancers after transplant.

    Accreditation Statement:

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.  

    Credit Designation 

    Physicians

    The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Method of Participation/How to Receive Credit:

    1. Review the activity objectives and CME/CE information.
    2. Participate in the CME/CE activity.
    3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

    Disclosure Policy:

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures:

    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

    Faculty Disclosures

    Faculty disclosures will be provided prior to the start of the activity.

    Commercial Supporter Disclosures

    No commercial support is provided for this webinar.

    Disclosure of Unlabeled Use:

    TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

    Disclaimer:

    The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the American Society for Transplantation and Cellular Therapy assume no liability for the information herein.

  • Barriers and Access to Transplant Care for Sickle Cell Patients

    Contains 1 Component(s) Includes a Live Web Event on 09/20/2021 at 2:00 PM (EDT)

    Join us on September 20 at 1 PM CT, for the third webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on challenges to finding stem cell sources and other barriers that both physicians and patients face throughout the process.

    Join us on September 20 at 1 PM CT, for the third webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on challenges to finding stem cell sources and other barriers that both physicians and patients face throughout the process. Other topics include:

    - Socioeconomic Barriers
    - Physicians attitude and practice
    - NMDP's Sickle Cell Warriors Program
    - Information about clinical trials

    This webinar will be moderated by Anna DeSalvo, a Senior Clinical Trials Patient Navigator with the NMDP Sickle Cell Warriors Program, and feature presentations by Dr. Lakshmanan Krishnamurti of Emory University. Each webinar in this series will also highlight patient's lived experiences within each of the topics.

    There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar by emailing info@astct.org. This webinar will be recorded and the recording and slides will be posted 24-48 hours after the live event.

    Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    Continuing Medical Education Information

    This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.                

    Statement of Need:

    The Sickle Cell Warriors Program at NMDP is a patient services program that assists in typing for patients, financial assistance, counseling, patient education and providing peer connections. The primary feedback from patients in the Sickle Cell Warrior Program is that #1 barrier to treatment is physicians. Patients report that they are not being told about all of their treatment options; regardless of disease severity, they should at least be made aware of various options, but often they are not. Many patients go to the Sickle Cell Warriors Program to enroll in a clinical trial for transplant, but this usually does not cover cost of HLA typing. In this case, the referring physician has not gone through the process of HLA typing, either because of misinformation or because the physician refuses to provide an order for typing simply because they don’t agree with patients physicians. This is a clear miscommunication between the community oncologists and transplant physicians. In surveys, transplant physicians identify a lack of awareness, lack of confidence, and reliance on outdated data from the referring physicians. These referring physicians in a similar survey reported that their primary reason for not communicating all treatment options was noncompliance in patients who they did not believe had the means to move forward with treatment. This illustrates a complex problem between the three groups (referring community physicians, transplant physicians, and the patients themselves) that this webinar series aims to address.

    Target Audience:

    This activity is intended for physicians, both referring physicians and transplant specialists, scientists, and other healthcare professionals who are part of the multidisciplinary team.

    Learning Objectives:

    Upon completion of this education activity, participants will be able to:

    1. Review potential challenges in finding an appropriate stem cell source, and enrolling in clinical trials.

    2. Identify potential socioeconomic barriers for patients in the transplant process, and relevant supports and programs to alleviate potential barriers and burdens.

    3. Examine any underlying hesitancy in colleagues in the field, to help engage colleagues in a meaningful way throughout the transplant process.

    Accreditation Statement:

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.  

    Credit Designation 

    Physicians

    The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Method of Participation/How to Receive Credit:

    1. Review the activity objectives and CME/CE information.
    2. Participate in the CME/CE activity.
    3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

    Disclosure Policy:

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures:

    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

    Faculty Disclosures

    Faculty disclosures will be provided prior to the start of the activity.

    Commercial Supporter Disclosures

    No commercial support is provided for this webinar.

    Disclosure of Unlabeled Use:

    TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

    Disclaimer:

    The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the American Society for Transplantation and Cellular Therapy assume no liability for the information herein.

  • FY2022 IPPS Final Rule Webinar

    Contains 2 Component(s)

    Join ASTCT Director of Government Relations, Alycia Maloney, JD and Reimbursement and Policy Advisors to ASTCT from Nimitt Consulting, Jugna Shah and Amy Rinkle, for the FY 2022 IPPS Final Rule webinar on September 16 at 11 a.m. CDT. The webinar will review FY 2022 IPPS final rule changes for CAR-T and allogeneic stem cell transplant, including financial and operational implications for providers.

    Join ASTCT Director of Government Relations, Alycia Maloney, JD and Reimbursement and Policy Advisors to ASTCT from Nimitt Consulting, Jugna Shah and Amy Rinkle, for the FY 2022 IPPS Final Rule webinar on September 16 at 11 a.m. CDT.

    Maloney, Shah, and Rinkle will cover:

    Government Relations (GR) and CMS Updates

    CAR-T, and other Cell Therapy Reimbursement Changes:
    - Use of FY 2019 data for FY 2022 rate-setting
    - Final payment policies for MS-DRG 018 for CAR-T
    - Change in MS-DRG naming and mapping of new therapies into MS-DRG 018
    - NTAP approvals for products in MS-DRG 018
    - Understanding CMS’ payment logic and reporting requirements for CAR-T clinical trial cases and expanded access cases CAR-T related ICD-10 coding updates
    - Understanding financial impact today and looking at reimbursement in the future

    Stem Cell Transplant (SCT) Reimbursement Changes:
    - Overall payment updates for autologous and allogeneic SCT
    - Final rule and Section 108 implications for MS-DRG 014
    - Operational requirements to receive cost reimbursement for all donor search and cell acquisition costs and expected financial impact
    - Other key updates

    There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar. If you are unable to join, the recording will be made available. Please consider sharing this webinar with your network of doctors, administrators, providers, or any other colleagues that may be interested.

  • Decision Making and Preparation for Transplant: Sickle Cell Patients and Clinical Perspectives

    Contains 4 Component(s), Includes Credits

    Join us on September 15 at 12:30 - 1:30 PM CT/1:30 - 2:30 PM ET, for the second webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on the decision making process for sickle cell patients and transplant.

    Join us on September 15 at 12:30 - 1:30 PM CT/1:30 - 2:30 PM ET, for the second webinar in the new ASTCT & NMDP Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This webinar will feature presentations from clinicians and patient speakers on the decision making process for sickle cell patients and transplant. Other topics include:

    - ASH Guidelines for BMT with Sickle Cell Disease
    - How to optimize patients for transplant
    - Patient selection criteria

    This webinar will be moderated by Dr. Folashade Otegbeye, and feature presentations by Dr. Santosh Saraf (UIC), and Dr. Mark Walters (UCSF). Each webinar in this series will also highlight patient's lived experiences within each of the topics.

    There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar by emailing info@astct.org. This webinar will be recorded and the recording and slides will be posted 24-48 hours after the live event.

    Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    Continuing Medical Education Information

    This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.                

    Statement of Need:

    The Sickle Cell Warriors Program at NMDP is a patient services program that assists in typing for patients, financial assistance, counseling, patient education and providing peer connections. The primary feedback from patients in the Sickle Cell Warrior Program is that #1 barrier to treatment is physicians. Patients report that they are not being told about all of their treatment options; regardless of disease severity, they should at least be made aware of various options, but often they are not. Many patients go to the Sickle Cell Warriors Program to enroll in a clinical trial for transplant, but this usually does not cover cost of HLA typing. In this case, the referring physician has not gone through the process of HLA typing, either because of misinformation or because the physician refuses to provide an order for typing simply because they don’t agree with patients physicians. This is a clear miscommunication between the community oncologists and transplant physicians. In surveys, transplant physicians identify a lack of awareness, lack of confidence, and reliance on outdated data from the referring physicians. These referring physicians in a similar survey reported that their primary reason for not communicating all treatment options was noncompliance in patients who they did not believe had the means to move forward with treatment. This illustrates a complex problem between the three groups (referring community physicians, transplant physicians, and the patients themselves) that this webinar series aims to address.

    Target Audience:

    This activity is intended for physicians, both referring physicians and transplant specialists, scientists, and other healthcare professionals who are part of the multidisciplinary team.

    Learning Objectives:

    Upon completion of this education activity, participants will be able to:


    1. Explain methods to optimize patients for transplant

    2. Identify the ASH Guidelines for BMT in Sickle Cell Disease

    3. Apply patient selection criteria to case studies.


    Accreditation Statement:

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.  

    Credit Designation 

    Physicians

    The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Method of Participation/How to Receive Credit:

    1. Review the activity objectives and CME/CE information.
    2. Participate in the CME/CE activity.
    3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

    Disclosure Policy:

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures:

    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

    Faculty Disclosures

    Faculty disclosures will be provided prior to the start of the activity.

    Commercial Supporter Disclosures

    No commercial support is provided for this webinar.

    Disclosure of Unlabeled Use:

    TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

    Disclaimer:

    The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the American Society for Transplantation and Cellular Therapy assume no liability for the information herein.

  • ASTCT Pharmacy SIG Online Journal Club - September 2021

    Contains 1 Component(s)

    The Pharmacy SIG Online Journal Club session will be presented on September 9, 2021 at 2pm CT/3pm ET.

    ASTCT Pharmacy SIG Journal Club Session – September 9, 2021

    Presenters & Articles

    Rebecca Rezac, PharmD
    PGY2 Oncology Resident
    UCHealth
    rebecca.rezac@uchealth.org

    Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients 

    Emily Ketchum, PharmD
    PGY-2 Oncology Pharmacy Resident
    Augusta University Medical Center
    eketchum@augusta.edu

    Belumosudil for Chronic Graft-versus-Host Disease (cGVHD) After 2 or More Prior Lines of Therapy: The ROCKstar Study

    Session Learning Objectives:
    Upon completion of the activity, participants should be able to:

    1. Discuss recent BMT pharmacy studies and their applications to current practice.
    2. Identify efficacy of SARS-CoV-2 vaccination and vaccine adverse events in patients receiving vaccination for SARS-CoV-2 following allogeneic hematopoietic stem cell transplant.
    3. Describe the evidence supporting belumosudil for chronic graft-versus-host disease (cGVHD) and identify the current place in therapy and clinical implications of belumosudil.  

    For full CE information, including presenter disclosures, and accreditation information, please click here to view and download the CE handout.

    This activity is jointly provided by The France Foundation and ASTCT. The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a post-test (>75%).

  • Referring Patients with Sickle Cell Disease to Transplant

    Contains 4 Component(s), Includes Credits

    This webinar aired on September 7 at 10 AM - 11 AM CT/11 AM - 12 PM ET. It is the first webinar in the new ASTCT & National Marrow Donor Program® (NMDP)/Be The Match®​ Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This first webinar featured presentations from clinicians and patient speakers on the referral process for patients with sickle cell disease to curative options with transplant.

    This webinar aired on September 7 at 10 AM - 11 AM CT/11 AM - 12 PM ET. It is the first webinar in the new ASTCT & National Marrow Donor Program® (NMDP)/Be The Match® Sickle Cell Webinar Series, in honor of Sickle Cell Awareness month. This first webinar featured presentations from clinicians and patient speakers on the referral process for patients with sickle cell disease to curative options with transplant. Other topics include:

    - General principles of referral and consultation
    - Psychosocial supports for patients in the referral process
    - Successful education models from New Jersey that connect community hematology and oncology physicians and transplant specialists.

    This webinar will be moderated by Dr. Maryam Zia, and feature presentations by Ana Gordon, a referral coordinator at University of Illinois at Chicago, and Dr. Jennifer Krajewski, from Hackensack Meridian Health. Each webinar in this series will also highlight patient's lived experiences within each of the topics.

    There will be a short Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar by emailing info@astct.org. This webinar will be recorded and the recording and slides will be posted 24-48 hours after the live event.

    Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

    Continuing Medical Education Information

    This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy.                

    Statement of Need:

    The Sickle Cell Warriors Program at NMDP is a patient services program that assists in typing for patients, financial assistance, counseling, patient education and providing peer connections. The primary feedback from patients in the Sickle Cell Warrior Program is that #1 barrier to treatment is physicians. Patients report that they are not being told about all of their treatment options; regardless of disease severity, they should at least be made aware of various options, but often they are not. Many patients go to the Sickle Cell Warriors Program to enroll in a clinical trial for transplant, but this usually does not cover cost of HLA typing. In this case, the referring physician has not gone through the process of HLA typing, either because of misinformation or because the physician refuses to provide an order for typing simply because they don’t agree with patients physicians. This is a clear miscommunication between the community oncologists and transplant physicians. In surveys, transplant physicians identify a lack of awareness, lack of confidence, and reliance on outdated data from the referring physicians. These referring physicians in a similar survey reported that their primary reason for not communicating all treatment options was noncompliance in patients who they did not believe had the means to move forward with treatment. This illustrates a complex problem between the three groups (referring community physicians, transplant physicians, and the patients themselves) that this webinar series aims to address.

    Target Audience:

    This activity is intended for physicians, both referring physicians and transplant specialists, scientists, and other healthcare professionals who are part of the multidisciplinary team.

    Learning Objectives:

    Upon completion of this education activity, participants will be able to:

    1. Describe the general principles for referring patients with sickle cell disease to transplant consultations.

    2. Identify areas of strengths and gaps for patient’s psychosocial support throughout the referral, decision making, and transplant process.

    3. Recognize opportunities for further communication and peer education with community oncologists, hematologists and transplant physicians in order to increase rates of getting sickle cell patients to curative options.

    Accreditation Statement:

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the American Society for Transplantation and Cellular Therapy. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.  

    Credit Designation 

    Physicians

    The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    Method of Participation/How to Receive Credit:

    1. Review the activity objectives and CME/CE information.
    2. Participate in the CME/CE activity.
    3. Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

    Disclosure Policy:

    In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

    Activity Staff Disclosures:

    The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

    The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular Therapy who control content have no relevant financial relationships to disclose.

    Faculty Disclosures

    Faculty disclosures will be provided prior to the start of the activity.

    Commercial Supporter Disclosures

    No commercial support is provided for this webinar.

    Disclosure of Unlabeled Use:

    TFF and ASTCT require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

    Disclaimer:

    The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the American Society for Transplantation and Cellular Therapy assume no liability for the information herein.

  • CAR T Toxicity Management and Grading

    Contains 2 Component(s)

    This webinar aired on August 30, at 2 PM CT and is the fourth installment of the CAR T Webinar Series from ASTCT. This webinar featured a presentation by Dr. Martina Pennisi, highlighting the key areas of CAR T toxicity management, including CRS/ICANS grading and management, as well as late post-infusion care. There was also a robust panel discussion on these topics moderated by Dr. Mariana Lucena, and featuring Dr. Shannon Maude, Dr. Sattva Neelapu, Dr. Yi Lin.

    This webinar aired on August 30, at 2 PM CT and is the fourth installment of the CAR T Webinar Series from ASTCT. This webinar featured a presentation by Dr. Martina Pennisi, highlighting the key areas of CAR T toxicity management, including CRS/ICANS grading and management, as well as late post-infusion care. There was also a robust panel discussion on these topics moderated by Dr. Mariana Lucena, and featuring Dr. Shannon Maude, Dr. Sattva Neelapu, Dr. Yi Lin.

  • 2021 Fundamentals of HCT Training Course eBook

    Contains 1 Component(s)

    The Fundamentals of HCT eBook provides up-to-date clinical information and covers the entire transplant process from pre-transplant consultation to post-transplant care. The book includes 30 chapters that highlight introduction to transplant, CAR-T, stem cell mobilization, pediatrics, and more!

    The Fundamentals of HCT eBook provides up-to-date clinical information and covers the entire transplant process from pre-transplant consultation to post-transplant care. The book includes 30 chapters that highlight introduction to transplant, CAR-T, stem cell mobilization, pediatrics, and more!

  • CAR-T vs. Transplant: Complements or Competitors?

    Contains 2 Component(s)

    This webinar aired on July 28, 2021 at 1 PM CT for the third installment of the CAR T Webinar Series from ASTCT. This webinar featured a presentation by Dr. Scott Goldsmith, highlighting the key areas of CAR T vs. Transplant, including consultation, day to day management, sequential therapy, and the pros and cons of each. The webinar also included a robust panel discussion on these topics moderated by Dr. Tania Jain, and featuring Dr. Samantha Jaglowski, Dr. John DiPersio, Dr. Brian Hill, and Dr. Mazyar Shadman.

    This webinar aired on July 28, 2021 at 1 PM CT for the third installment of the CAR T Webinar Series from ASTCT. This webinar featured a presentation by Dr. Scott Goldsmith, highlighting the key areas of CAR T vs. Transplant, including consultation, day to day management, sequential therapy, and the pros and cons of each. The webinar also included a robust panel discussion on these topics moderated by Dr. Tania Jain, and featuring Dr. Samantha Jaglowski, Dr. John DiPersio, Dr. Brian Hill, and Dr. Mazyar Shadman.


    Speaker and Moderator Bios:

    - Dr. Tania Jain is an Assistant professor of oncology at Johns Hopkins and also leads the adult CAR T program at Hopkins. She currently serves as Vice Chair to the ASTCT Committee on Education, and is an active member of other ASTCT Committees and Special Interest Groups.
    - Dr. Scott Goldsmith is a newly graduated heme onc fellow from Washington University, St Louis and is on his way to City of Hope, Los Angeles (via Florida btw) to start his new faculty position as assistant professor in a week.
    - Dr. Mazyar Shadman is an associate professor at University of Washington (UW) and Fred Hutchinson Cancer Research Center. He is a hematologic malignancies expert who specializes in treating patients with lymphoma/ chronic lymphocytic leukemia (CLL). He is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR-T cell), and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL.  
    - Dr. Brian Hill is the Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma.  He is the principal investigator of multiple on-going clinical trials of developmental therapeutics including novel cellular therapies.  
    - Dr. John F. DiPersio, Deputy Director, Alvin J. Siteman Cancer Center, Director, Center for Gene and Cellular Immunotherapy and Chief of the Division of Oncology at Washington University School of Medicine in St. Louis. Dr. DiPersio’s research focuses on fundamental and translational aspects of leukemia and stem cell biology.
    - Dr. Samantha Jaglowski is an associate professor of hematology and the medical director of the Blood and Marrow Transplant Program at The Ohio State University, specializing in stem cell transplants for patients battling lymphoma and CLL. Her current research includes a phase II study of CTL-019, a CD19-specific CAR-T therapy for the treatment of diffuse large B-cell lymphoma (DLBCL)

  • Clinical Advances in CAR T-Cell Therapy

    Contains 2 Component(s)

    The second in ASTCT's CAR-T Webinar Series aired on June 29, 2021 at 2 PM CT with Dr. Frederick Locke, and our moderator, Dr. Akshay Sharma. This webinar, 'Clinical Advances in CAR T-Cell Therapy' covered a review of approved CAR-T products, practical aspects of referrals, eligibility, leukapheresis, and more!

    The second in ASTCT's CAR-T Webinar Series aired on June 29, 2021 at 2 PM CT with speaker, Dr. Frederick Locke, and our moderator, Dr. Akshay Sharma. This webinar, 'Clinical Advances in CAR T-Cell Therapy' covered a review of approved CAR-T products, practical aspects of referrals, eligibility, leukapheresis, and more! If you have any questions you would like to submit for the Q&A with Dr. Locke, please email info@astct.org.

    Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.